04:05 AM EDT, 07/09/2024 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Monday that Taiho Pharmaceutical exercised its option for an exclusive license to quemliclustat, an investigational small molecule CD73 inhibitor, in Japan and some other territories in Asia.

This marks the fourth option exercise by Taiho to an Arcus program, based on a license agreement between the two companies in September 2017.

In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment and additional payments upon the achievement of certain milestones, as well as royalties on net sales, if any products from the program are approved.

Price: 13.83, Change: -0.01, Percent Change: -0.07